期刊文献+

不同方案治疗卵巢上皮性癌的疗效比较 被引量:1

Therapeutic effect of different treatment progarams for epithelial ovarian cancer
原文传递
导出
摘要 目的 探讨不同方案治疗卵巢上皮性癌的临床疗效.方法 选择卵巢上皮性癌患者共265例,分为A、B两组,就其手术方式、化疗方案及疗效进行比较.两组手术方式基本相同,A组采用PAC化疗方案,B组采用TC方案.结果 两组肿瘤残留病灶直径〉2 cm者分别占29.2%、14.2%,临床缓解率、部分缓解牢差异无统计学意义,有效率分别为51.7%、81.4%(P〈0.05).A组的1、2、3、4、5年生存率分别为90.2%、86.9%、62.7%、45.8%、32.7%,中位生存期和无复发生存期分别为37.9个月和17.4个月;B组的1、2、3、4、5年生存率分别为94.3%、91.1%、68.7%、56.4%、44.2%,中位生存期、无复发生存期分别为50.5个月和32.2个月;两组5年生存率、中位生存期、无复发生存期间差异有统计学意义(P〈0.01或〈0.05).结论 手术残留病灶的大小及化疗方案影响卵巢上皮性癌的疗效,TC化疗方案优越于PAC化疗方案. Objective To explore different methods on the efficacy of epithelial ovarian cancer.Methods The patients with epithelial ovarian cancer,a total of 265 cases,who was treated were selected and divided into A,B groups.Its surgical,chemotherapy and efficacy were compared.It was basically the same between the two surgical.On chemotherapy,A group was given PAC program mainly,B group Was given TA program mainly.Results Diameter of residual tumor lesions〉2 cm respectively accounted for 29.2%.14.2%.The difference of clinical remission rate,partial remission rate was not significant.Effective rates were respectively 51.7% and 81.4%(P〈0.05).To group A,the survival rates of 1-year,2-years,3-years,4-years,5-years were respectively 90.2%,86.9%,62.7%,45.8%,32.7%:The median survival period and relapse-free survival time was respectively 37.9 months and 17.4 months.To group B,the survival rates of 1-year,2-years,3-years,4-years,5-years were respectively 94.3%、91.1%、68.7%、56.4%、44.2%;The median survival period and relapse-free survival time wag respectively 50.5 months and 32.2 months.The difference of 5-years survival rate,median survival,relapse-free survival of the two groups was statistically significant(P〈0.01 or 0.05).Conclusions The size of postoperative residual disease and the chemotherapy im-paeted the efficacy of epithelial ovarian cancer.TC chemotherapy was superior to PAC chemotherapy.
作者 林少梅
出处 《中国基层医药》 CAS 2010年第12期1590-1591,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 卵巢肿瘤 抗肿瘤联合化疗方案 Ovarian neoplasms Antineoplastic combined chemotherapy protocols
  • 相关文献

参考文献10

  • 1Yancik R.Ovarian Cancer;age contrasts in incidence,histology disease stage at diagnosis and mortality.Cancer,1993,71 (4):517-523.
  • 2Thigpen TJ,Vance RB,Khansur T.Second-line chemotherapy for recurrent careinoma of the ovary.Cancer,1993,71 (4supp):1559-1564.
  • 3李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 4Bristow RE,Tomacruz RS,Armstrong DK,,et al.Surrinal effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the plantinum eraia meta-analysis.J Clin Oncol,2002,20(6):1248-1259.
  • 5Bristow RE.Predicting surgical outcome for advanced ovarian cancer,surgical standards of care,and the concept of Kaizen.Gy-necol Oncol,2009,112(1):1-3.
  • 6Delcayre A,Le Pecq JB.Exosomes as novel therapeutic nanode-vices.Curr Opín Mol Ther,2006,8(1):31-38.
  • 7曲延文,刘淑美,李赟霞.卵巢癌术后腹腔化疗的护理[J].中国基层医药,2008,15(9):1577-1577. 被引量:1
  • 8Suisher EM,Mutcg DC,Kader JS,et al.Topotecan in platinum and paclitaxel-resistant ovarian cancer.Gynecol oncol,1997,66(3):480-486.
  • 9McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophosp-hamide and Crisplatin compared with paclitaxel and cosplatin in patients with stage and stage IV ovarian Cancer.N Engl J Med,1996,334.
  • 10Mc Gurie WP,Hoskins WJ,Brady MF,et al.Taxol and ciaplatin (TP) improves outcome in advanced ovarian cancer (A0C) as compared to cytoxan and cosplatin(CP).Proc ASCO,1995,14 (1):275.

二级参考文献23

  • 1程晓趁,张芳,刘璇.恶性肿瘤术后腹腔化疗的护理体会[J].山东医药,2005,45(17):2-2. 被引量:2
  • 2张慧兰 陈容秀.肿瘤护理学[M].天津:天津科学技术出版社,1999,8..
  • 3Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice.J Clin Pathol,2005,58:308-312.
  • 4Jacobs I. Discussion:ovarian cancer screening. Gynecol Oncol,2003,88:80-83.
  • 5Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359(9306): 572-577.
  • 6Kozak KR, Amneus MW, Pusey SM,et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.Proc Natl Acad Sci U S A, 2003,100:12343-12348.
  • 7Kalofonos HP, Giannakenas C, Kosmas C, et al. Radioimmunoscintigraphy in patients with ovarian cancer. Acta Oncol,1999,38:629-634.
  • 8Lieberman G, Buscombe JR, Hilson AJ, et al. Preoperative diagnosis of ovarian carcinoma with a novel monoclonal antibody.Am J Obstet Gynecol,2000,183:534-540.
  • 9Wilder JL, Pavlik E, Straughn JM,et al. Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol,2003,89:233-235.
  • 10Topuz E, Aydiner A, Saip P, et al. Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.Eur J Gynaecol Oncol,2000,21:599-602.

共引文献73

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部